BioSpace News Archive

Chicago, Illinois--(Newsfile Corp. - January 13, 2021) - TTC Oncology (“TTC” or the “Company”) CEO and CMO Arek Dudek, MD, PhD, will be participating in the Biotech Showcase virtual conference occurring January 11-15, 2021.

Promaxo, Inc., the medical imaging, robotics, and AI technology company, and Huami Corp. announced closing an investment round of $4.17M led by Huami.

Description: The core objective of the business intelligence report on ‘global life science tools market’ is to illuminate the different segments and regions in terms of sizes and shares, and forecast the values for 2020-2027.

As the resurgence of COVID-19 activity continues in Canada , we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity. The following is the latest summary on national numbers a

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the development of further CDx tests for A2’s other clinical development programs

Helix BioPharma Corp. (TSX:HBP) a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.

TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of $40.0 million before deducting fees and other estimated offering expenses.

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Noble Capital Markets 17th Annual Small & Microcap Investor Conference

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2020.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual J.P. Morgan Healthcare Conference.